Antibody responses to trivalent inactivated influenza vaccine in health care personnel previously vaccinated and vaccinated for the first time

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Huang, Kuan Ying A ^a,b   Chang, Shih Cheng ^b   Huang, Yhu Chering ^a   Chiu, Cheng Hsun ^a,b   Lin, Tzou Yien ^a,c,d  

^a CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d Ministry of Health and Welfare   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; VIRUS ANTIBODY; VIRUS HEMAGGLUTININ;

ADOLESCENT; ADULT; ANTIBODY PRODUCTION; BLOOD; FEMALE; HEALTH CARE PERSONNEL; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SECONDARY IMMUNIZATION; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; FEMALE; HEALTH PERSONNEL; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS, VIRAL; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINATION; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 85010053659     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep40027     Document Type: Article

References (58)

1. Grohskopf, L. A. et al. Prevention and Control of Infuenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Infuenza Season. MMWR Morb Mortal Wkly Rep 64, 818-825 (2015).
2. Chow, A., Ma, S., Ling, A. E. & Chew, S. K. Infuenza-associated deaths in tropical Singapore. Emerg Infect Dis 12, 114-121 (2006).
3. Couch, R. B. Seasonal inactivated infuenza virus vaccines. Vaccine 26 Suppl 4, D5-9 (2008).
4. Francis, T. & Magill, T. P. The antibody response of human subjects vaccinated with the virus of human infuenza. J Exp Med 65, 251-259 (1937).
5. Hobson, D., Curry, R. L., Beare, A. S. & Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with infuenza A2 and B viruses. J Hyg (Lond) 70, 767-777 (1972).
6. Skehel, J. J. & Wiley, D. C. Receptor binding and membrane fusion in virus entry: the infuenza hemagglutinin. Annu Rev Biochem 69, 531-569 (2000).
7. Cox, R. J., Brokstad, K. A. & Ogra, P. Infuenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated infuenza vaccines. Scand J Immunol 59, 1-15 (2004).
8. Sridhar, S., Brokstad, K. A. & Cox, R. J. Infuenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Infuenza Vaccines. Vaccines (Basel) 3, 373-389 (2015).
9. Nelson, M. I. & Holmes, E. C. The evolution of epidemic infuenza. Nat Rev Genet 8, 196-205 (2007).
10. Worldwide Infuenza Centre: Annual and interim reports (2016). Available at: https://crick.ac.uk/research/worldwide-infuenza-centre/annual-and-interim-reports/. (Accessed: 28th May 2016).
11. Huang, K. Y. et al. Focused antibody response to infuenza linked to antigenic drif. J Clin Invest 125, 2631-2645 (2015).
12. Petrie, J. G., Ohmit, S. E., Johnson, E., Truscon, R. & Monto, A. S. Persistence of Antibodies to Infuenza Hemagglutinin and Neuraminidase Following One or Two Years of Infuenza Vaccination. J Infect Dis 212, 1914-1922 (2015).
13. Uyeki, T. M. Preventing and controlling infuenza with available interventions. N Engl J Med 370, 789-791 (2014).
14. Salgado, C. D., Farr, B. M., Hall, K. K. & Hayden, F. G. Infuenza in the acute hospital setting. Lancet Infect Dis 2, 145-155 (2002).
15. Stott, D. J., Kerr, G. & Carman, W. F. Nosocomial transmission of infuenza. Occup Med (Lond) 52, 249-253 (2002).
16. Babcock, H. M., Gemeinhart, N., Jones, M., Dunagan, W. C. & Woeltje, K. F. Mandatory infuenza vaccination of health care workers: translating policy to practice. Clin Infect Dis 50, 459-464 (2010).
17. Pearson, M. L., Bridges, C. B. & Harper, S. A. Healthcare Infection Control Practices Advisory Committee (HICPAC); Advisory Committee on Immunization Practices (ACIP). Infuenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55, 1-16 (2006).
18. Black, C. L. et al. Infuenza Vaccination Coverage Among Health Care Personnel-United States, 2014-15 Infuenza Season. MMWR Morb Mortal Wkly Rep 64, 993-999 (2015).
19. Ahmed, R. & Gray, D. Immunological memory and protective immunity: understanding their relation. Science 272, 54-60 (1996).
20. Dörner, T. & Radbruch, A. Antibodies and B cell memory in viral immunity. Immunity 27, 384-392 (2007).
21. Hoskins, T. W., Davies, J. R., Smith, A. J., Miller, C. L. & Allchin, A. Assessment of inactivated infuenza-A vaccine afer three outbreaks of infuenza A at Christ's Hospital. Lancet 1, 33-35 (1979).
22. Smith, D. J., Forrest, S., Ackley, D. H. & Perelson, A. S. Variable efcacy of repeated annual infuenza vaccination. Proc Natl Acad Sci USA 96, 14001-14006 (1999).
23. McLean, H. Q. et al. Impact of repeated vaccination on vaccine efectiveness against infuenza A(H3N2) and B during 8 seasons. Clin Infect Dis 59, 1375-1385 (2014).
24. Tompson, M. G. et al. Efects of Repeated Annual Inactivated Infuenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11. Vaccine 34, 981-988 (2016).
25. Skowronski, D. M. et al. A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Efectiveness During the 2014-2015 Season. Clin Infect Dis 63, 21-32 (2016).
26. Krause, J. C. et al. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the infuenza H1N1 virus hemagglutinin. J Virol 85, 10905-10908 (2011).
27. Ekiert, D. C. et al. Antibody recognition of a highly conserved infuenza virus epitope. Science 324, 246-251 (2009).
28. Corti, D. et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal infuenza vaccine. J Clin Invest 120, 1663-1673 (2010).
29. Li, G. M. et al. Pandemic H1N1 infuenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci USA 109, 9047-9052 (2012).
30. Iba, Y. et al. Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 infuenza viruses. J Virol 88, 7130-7144 (2014).
31. Benjamin, E. et al. A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the infuenza virus H3 hemagglutinin globular head. J Virol 88, 6743-6750 (2014).
32. Sasaki, S. et al. Infuence of prior infuenza vaccination on antibody and B-cell responses. PLoS One 3, e2975 (2008).
33. Andrews, S. F. et al. High preexisting serological antibody levels correlate with diversifcation of the infuenza vaccine response. J Virol 89, 3308-3317 (2015).
34. Beyer, W. E. et al. Efects of repeated annual infuenza vaccination on vaccine sero-response in young and elderly adults. Vaccine 14, 1331-1339 (1996).
35. de Bruijn, I. A. et al. Quality and quantity of the humoral immune response in healthy elderly and young subjects afer annually repeated infuenza vaccination. J Infect Dis 179, 31-36 (1999).
36. Davenport, F. M. & Hennessy, A. V. A serologic recapitulation of past experiences with infuenza A; antibody response to monovalent vaccine. J Exp Med 104, 85-97 (1956).
37. Webster, R. G. Original antigenic sin in ferrets: the response to sequential infections with infuenza viruses. J Immunol 97, 177-183 (1966).
38. Kim, J. H., Skountzou, I., Compans, R. & Jacob, J. Original antigenic sin responses to infuenza viruses. J Immunol 183, 3294-3301 (2009).
39. Powers, D. C. & Belshe, R. B. Vaccine-induced antibodies to heterologous infuenza A H1N1 viruses: efects of aging and "original antigenic sin". J Infect Dis 169, 1125-1129 (1994).
40. Wrammert, J. et al. Rapid cloning of high-afnity human monoclonal antibodies against infuenza virus. Nature 453, 667-671 (2008).
41. Sasaki, S. et al. Limited efcacy of inactivated infuenza vaccine in elderly individuals is associated with decreased production of vaccine-specifc antibodies. J Clin Invest 121, 3109-3119 (2011).
42. Frasca, D., Diaz, A., Romero, M. & Blomberg, B. B. The generation of memory B cells is maintained, but the antibody response is not, in the elderly afer repeated infuenza immunizations. Vaccine 34, 2834-2840 (2016).
43. Andrews, S. F. et al. Immune history profoundly afects broadly protective B cell responses to infuenza. Sci Transl Med 7, 316ra192 (2015).
44. Couch, R. B. et al. Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent infuenza vaccines. Vaccine 31, 190-195 (2012).
45. Kendal, A. P., Bozeman, F. M. & Ennis, F. A. Further studies of the neuraminidase content of inactivated infuenza vaccines and the neuraminidase antibody responses afer vaccination of immunologically primed and unprimed populations. Infect Immun 29, 966-971 (1980).
46. Kilbourne, E. D., Cerini, C. P. , Khan, M. W. , Mitchell, J. W. Jr. & Ogra, P. L. Immunologic response to the influenza virus neuraminidase is infuenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J Immunol 138, 3010-3013 (1987).
47. Powers, D. C., Kilbourne, E. D. & Johansson, B. E. Neuraminidase-specifc antibody responses to inactivated infuenza virus vaccine in young and elderly adults. Clin Diagn Lab Immunol 3, 511-516 (1996).
48. Sultana, I. et al. Stability of neuraminidase in inactivated infuenza vaccines. Vaccine 32, 2225-2230 (2014).
49. Jahiel, R. I. & Kilbourne, E. D. Reduction in plaque size and reduction in plaque number as difering indices of infuenza virus-antibody reactions. J Bacteriol 92, 1521-1534 (1966).
50. Kilbourne, E. D., Laver, W. G., Schulman, J. L. & Webster, R. G. Antiviral activity of antiserum specifc for an infuenza virus neuraminidase. J Virol 2, 281-288 (1968).
51. Cate, T. R. et al. A high dosage infuenza vaccine induced signifcantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 28, 2076-2079 (2010).
52. Couzens, L. et al. An optimized enzyme-linked lectin assay to measure infuenza A virus neuraminidase inhibition antibody titers in human sera. J Virol Methods 210, 7-14 (2014).
53. Murphy, B. R., Kasel, J. A. & Chanock, R. M. Association of serum anti-neuraminidase antibody with resistance to infuenza in man. N Engl J Med 286, 1329-1332 (1972).
54. Couch, R. B., Kasel, J. A., Gerin, J. L., Schulman, J. L. & Kilbourne, E. D. Induction of partial immunity to influenza by a neuraminidase-specifc vaccine. J Infect Dis 129, 411-420 (1974).
55. Couch R. B. et al. Antibody correlates and predictors of immunity to naturally occurring infuenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 207, 974-981 (2013).
56. Memoli M. J. et al. Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Infuenza A/H1N1 Virus Healthy Human Challenge Model. MBio 7, e00417-16 (2016).
57. Johansson, B. E., Moran, T. M. & Kilbourne, E. D. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between infuenza A virus surface glycoproteins. Proc Natl Acad Sci USA 84, 6869-6873 (1987).
58. Kilbourne, E. D. Comparative efcacy of neuraminidase-specifc and conventional infuenza virus vaccines in induction of antibody to neuraminidase in humans. J Infect Dis 134, 384-394 (1976).